文献速递银屑病与炎症性皮肤病

依奇珠单抗治疗中重度银屑病长达5年的药物留存、疗效与安全性

Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-12-26

260周药物留存率为65.5%,超级应答者停药风险更低;观察患者中PASI100、PASI90和PASI≤3在16周分别为54.1%、60.5%和73%,在260周分别为59.1%、81.8%和95.5%;未观察到严重不良事件。

要点

  • 260周药物留存率为65.5%,约三分之二患者持续治疗。
  • 16周达PASI100并维持至28周的超级应答者停药风险更低。
  • 未观察到严重不良事件。

核心结论

  • 依奇珠单抗在中重度银屑病或银屑病关节炎真实世界队列中长达5年显示高疗效与安全性,药物留存率约三分之二。
  • 治疗早期快速应答可预测长期应答。

研究设计与样本

  • 采用Cox分析评估停药预测因素,Logistic回归识别应答预测因素,疗效在16、52、104、156、208和260周的观察患者中评估。

主要发现

  • 260周药物留存率为65.5%。
  • 超级应答者(16周达PASI100并维持至28周)与更低的停药风险相关。
  • 观察患者中PASI100、PASI90和PASI≤3在16周分别为54.1%、60.5%和73%,在260周分别为59.1%、81.8%和95.5%。
  • 较高的平均BMI是早期时间点应答较差的唯一强相关因素:16周PASI100(OR 0.93,CI 0.87-0.98,p=0.014)、104周PASI100(OR 0.91,CI 0.84-0.98,p=0.019)、16周PASI90(OR 0.94,CI 0.88-0.99,p=0.028)、104周PASI90(OR 0.91,CI 0.83-0.99,p=0.027)、104周PASI≤3(OR 0.86,CI 0.76-0.97,p=0.018)。
  • 未观察到严重不良事件。

关键数值与推荐

  • 260周药物留存率65.5%。
  • 16周PASI100、PASI90、PASI≤3分别为54.1%、60.5%、73%;260周分别为59.1%、81.8%、95.5%。

临床怎么用

  • 依奇珠单抗可用于中重度银屑病或银屑病关节炎的长期治疗,5年药物留存率约三分之二。
  • 早期快速应答(16周PASI100并维持至28周)提示长期应答较好,可支持继续治疗决策。
  • 高BMI患者早期应答可能较差,需关注体重管理并加强疗效监测。

局限性

  • 原文未报告具体样本量。
  • 疗效分析基于观察患者,可能存在选择偏倚。
  • 真实世界单队列数据,预测因素分析为探索性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ixekizumab proved to be effective and safe for psoriasis treatment in several randomized clinical trials and real-life studies. Nevertheless, long-term real-world experiences are still lacking, with little data up to 4 years of treatment. OBJECTIVES: To analyse survival, effectiveness and safety of ixekizumab in a real-life cohort of patients affected by moderate-to-severe psoriasis or psoriatic arthritis up to 260 weeks (5 years). METHODS: We included all patients treated with ixekizumab from December 2017 to March 2021. Drug survival (DS) was analysed in patients at risk for up to 5 years. Cox analysis was adopted to evaluate possible predictive factors of discontinuation. Psoriasis Area Severity Index (meanPASI and PASI100, 90, and ≤3) was used as outcomes of effectiveness on observed patients at 16, 52, 104, 156, 208 and 260 weeks. Logistic regression was performed to identify possible predictive factors of response. RESULTS: DS was 65.5% at 260 weeks, with being a super-responder patient (achievement of PASI100 at 16 weeks and maintained at 28 weeks) correlated with less risk of discontinuation. PASI100, 90 and ≤3 was achieved by 54.1%, 60.5% and 73% of observed patients, respectively, at 16 weeks, and by 59.1%, 81.8% and 95.5%, respectively, at 260 weeks. High mean BMI was the only factor strongly associated with less achievement of the outcomes at the earlier time points: PASI100 at 16 weeks (OR 0.93, CI 0.87-0.98, p = 0.014) and at 104 weeks (OR 0.91, CI 0.84-0.98, p = 0.019), PASI90 achievement at 16 weeks (OR 0.94, CI 0.88-0.99, p = 0.028) and 104 weeks (OR 0.91, CI 0.83-0.99, p = 0.027), and PASI ≤3 (OR 0.86, CI 0.76-0.97, p = 0.018) at 104 weeks. No severe adverse events were observed. CONCLUSIONS: Ixekizumab showed high effectiveness and safety for up to 5 years, with survival of 2/3 of treated patients. Rapid response to treatment is predictive of long-term response.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Mastorino L, Dapavo P, Burzi L, et al. Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years. J Eur Acad Dermatol Venereol. 2023. PMID: 38147467. doi:10.1111/jdv.19682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。